长春瑞滨联合奥沙利铂治疗晚期非小细胞肺癌的临床观察

Vinorelbine plus oxaliplatin in treatment of advanced non-small-cell lung cancer

目的观察长春瑞滨(NVB)加奥沙利铂(LOHP)治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副反应。方法经病理组织学或细胞学证实的48例晚期非小细胞肺癌患者,随机分为治疗组25例及对照组23例,分别给予NVB+LOHP及NVB+CDDP治疗,21天为一个周期,均治疗2周期以上。结果治疗组总有效率为44.0%,对照组总有效率为39.1%(P>0.05)。毒副反应以白细胞降低,胃肠道反应和周围神经炎为主,而～度消化道反应、肾脏损害及心功能下降主要发生在对照组,周围神经炎主要发生在治疗组(P<0.05),但均可耐受。结论长春瑞滨加奥沙利铂与长春瑞滨加顺铂治疗晚期非小细胞肺癌相似,均有较好的近期疗效,而长春瑞滨加奥沙利铂组的毒副反应较轻,临床应用更安全,更适合于老年患者。

Objective To evaluate the efficacy and toxicity of vinorelbine and oxaliplatin in the treatment of advanced non-small-cell lung cancer （NSCLC）. Methods A total of 48 patients with advanced NSCLC diagnosed by pathology were randomly divided into two groups. Vinorelbinc and oxaliplatin were administrated to the patients in the study group （n=25）, and vinorelbine and cisplatin in the control group （n=23）, with 21 days as a cycle. All patients received at least two cycle treatment. Results The overall response rate was 44.0% in the study group and 39.1% in the control group （P〉0.05）. The main toxicities were well tolerated, which consisted of leukopenia, nausea/vomiting and peripheral neuritis. Grades Ⅲ -Ⅳ nausea/vomlting, renal toxicity and cardiac insufficiency occurred more frequently in the control group than in the study group, whereas peripheral neuritis occurred more frequently in the study group than in the control group （P〈 0. 05）. Conclusion Both of the two regimens of vinorelbine plus oxaliplatin and vinorelhine plus cisplatin are feasible, well tolerated and effective in the treatment of advanced NSCLC, and the former may he safer than the latter for the older patients.